Contego Medical Receives CE Mark Approval for Next Generation Carotid Stent
ncarol.com/10111703

RALEIGH, N.C., April 16, 2021 /PRNewswire/ -- Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP^® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).

The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure.  The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.

More on ncarol.com

• CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
• PRÝNCESS Builds Anticipation With "My Nerves" — A Girls-Girl Anthem
• Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
• From Sleepless Nights to Sold-Out Drops: Catch Phrase Poet's First Year Redefining Motivational Urban Apparel
• Now Live on Kickstarter: The Bottle That Chills and Purifies Any Freshwater — and Donates One for Every 10 Backers

The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days¹.

"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."

Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."

More on ncarol.com

• How Specialized Game Development Services Are Powering the Next Wave of Interactive Entertainment
• Don't Settle for a Lawyer Who Just Speaks Spanish. Demand One Who Understands Your Story
• Dan Williams Promoted to Century Fasteners Corp. – General Manager, Operations
• Ski Johnson Inks Strategic Deals with Three Major Food Chain Brands
• NIL Club Advances Agent-Free NIL Model as Oversight Intensifies Across College Athletics

About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.

In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.

Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.

¹ LINC 2020

SOURCE Contego Medical, Inc.

---

Show All News | Report Violation